Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Small molecule
Partner/Sponsor/Collaborator: Bristol-Myers Squibb
Deal Size: $1,220.0 million Upfront Cash: $50.0 million
Deal Type: Collaboration August 18, 2021
The in-licensed candidate targets a critical immunological kinase that historically has proven difficult to target due to the need for a combination of potency, selectivity, and overall drug-like properties.